

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

Reference AL for
Serial No. 10/786,886

(51) International Patent Classification ⁶ : A61K 31/70, 9/48		A1	(11) International Publication Number: WO 99/32128
			(43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: PCT/US98/26222		(US). VADINO, Winston, A. [US/US]; 9 Glenmont Road, Whitehouse Station, NJ 08889 (US). BOWEN, Frank, E. [US/US]; 26 Jackson Avenue, Rutherford, NJ 07070 (US). (74) Agents: HOFFMAN, Thomas, D. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(22) International Filing Date: 21 December 1998 (21.12.98)			
(30) Priority Data: 08/997,172 22 December 1997 (22.12.97) US 08/997,169 22 December 1997 (22.12.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 08/997,169 (CIP) Filed on 22 December 1997 (22.12.97) US 08/997,172 (CIP) Filed on 22 December 1997 (22.12.97)			
(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LIEBOWITZ, Stephen, M. [US/US]; 70 Beechwood Circle, Neshanic Station, NJ 08853 (US). STUPAK, Elliot, I. [US/US]; 11 Woodland Road, West Caldwell, NJ 07006 (US). CHAUDRY, Imtiaz, A. [US/US]; 18 Rose Avenue, North Caldwell, NJ 07006			
(54) Title: ORALLY ADMINISTABLE SOLID RIBAVIRIN DOSAGE FORMS AND PROCESS FOR MAKING THEM			
(57) Abstract An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin and a process for making such solid dosage forms are disclosed			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5 **ORALLY ADMINISTRABLE SOLID RIBAVIRIN DOSAGE FORMS
AND PROCESS FOR MAKING THEM**

Background of the Invention

 This invention relates to an orally administrable solid dosage form
10 comprising a compacted ribavirin composition and process for making such
solid dosage forms. The compacted ribavirin composition of this invention
has an advantageously high tap density as well as surprisingly fast
disintegration and dissolution rates and contains a freely flowing ribavirin of
uniform physical characteristics which is substantially free of other
15 polymorphic forms.

 Ribavirin is an antiviral agent which is currently being administered in
association with interferon alpha-2b to treat patients with chronic hepatitis C
infections.

 Ribavirin 200 mg capsules are manufactured and marketed by ICN
20 Pharmaceuticals in Canada under the trade name Virazole™ capsules. The
ribavirin used to make the ribavirin composition in the Virazole capsules is a
non-freely flowing powder with low and variable tap densities in the range of
0.320 to 0.449 g/mL. A ribavirin composition with a tap density of at least 0.6
g/mL is needed for the uniform filling of the 200 mg capsules. It would be
25 desirable for the ribavirin composition to have a uniformly high tap density of
at least 0.6 g/mL to fill any capsule and to avoid excessive weight variation
and excessive packing in the capsule shell during the capsule filling
operation especially in the high speed capsule filling equipment which
operate at a fill rate of over 20,000 capsules per hour.

30 Dry compacting of the ribavirin formulation would be an attractive
solution to this problem so long as the heat produced during the compaction
operation does not cause the formation of ribavirin polymorphic forms, which
forms are unacceptable for obtaining health registration.

 The Virazole capsules exhibited inconsistency in meeting the
35 dissolution specifications which requires that 80% of the ribavirin be
dissolved in water in 30 minutes. The disintegration times of the Virazole
composition were typically around 20 minutes.

 There is a need for a ribavirin composition with a tap density of at
least 0.6 g/mL and having improved dissolution rates and reduced
40 disintegration times. There is also a need to compact the ribavirin

composition to achieve such high tap densities while maintaining the ribavirin in the physical state substantially free of polymorphic forms.

Summary of the Invention

5

The invention provides an orally administrable solid dosage form comprising a rapidly dissolving compacted ribavirin composition comprising ribavirin and a pharmaceutically acceptable disintegrant wherein said composition after dry compaction has a tap density of at least about 0.6 g/mL and wherein more than 80% by weight of the ribavirin dissolves in water in about 30 minutes.

10

The invention also provides a rapidly dissolving compacted ribavirin composition comprising:

15

(a) an antivirally effective amount of ribavirin;

20

(b) an effective amount of at least one filler selected from the group consisting of lactose anhydrous, lactose monohydrate, sucrose, mannitol, microcrystalline cellulose, pregelatinized starches, dibasic calcium phosphate dihydrate, calcium sulfate dihydrate and calcium sulfate trihydrate;

25

(c) an effective amount of a pharmaceutically acceptable disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, corn starch, pregelatinized starches, sodium carboxymethyl cellulose, potato starch, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, magnesium aluminium silicate, bentonite, alginic acid and alginates; and;

30

(d) an effective amount of a lubricant selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG 4000, PEG 5000, PEG 6000, and stearic acid;

35

and, wherein the tap density of the compacted composition is at least about 0.6 g/mL.

In a preferred embodiment, the invention further provides is a rapidly dissolving compacted ribavirin composition comprising of:

5	<u>Ingredient</u>	<u>mg</u>
	Ribavirin USP	150.0 to 250.0
	Lactose Monohydrate NF	30.0 to 50.0
	Microcrystalline Cellulose NF	37.5 to 62.5
	Croscarmellose Sodium NF	4.5 to 7.5
10	Magnesium Stearate NF	2.25 to 5.0

and wherein the tap density of the compacted composition is at least about 0.6 g/mL.

15 In a preferred embodiment, the invention provides a rapidly dissolving compacted ribavirin composition comprising:

	<u>Ingredient</u>	<u>mg</u>
	Ribavirin USP	200.0
20	Lactose Monohydrate NF	40.0
	Microcrystalline Cellulose NF	50.0
	Croscarmellose Sodium NF	6.0
	Magnesium Stearate NF	4.0

25 wherein the tap density of the compacted composition is at least about 0.6 g/mL; and

wherein the ribavirin is substantially free of polymorphic forms of ribavirin.

30 In another aspect, this invention provides a method of producing a rapidly dissolving compacted ribavirin composition which comprises the steps of:

(a) admixing an antivirally effective amount of ribavirin, an effective amount of a pharmaceutically acceptable disintegrant, and an effective amount of at least one filler for a time sufficient to form a homogeneous mixture;

35

b) compacting the homogeneous mixture of Step (a) at a compressing force in the range of about 50 to about 75 kN for a time sufficient to produce an acceptable compact wherein the ribavirin is substantially free of polymorphic forms ; and

5

c) admixing the acceptable compact of Step (b) with an effective amount of a lubricant for a time sufficient to produce a rapidly dissolving compacted ribavirin composition.

10

Detailed Description of the Invention

We have surprisingly discovered that we can consistently manufacture a uniform ribavirin composition which consistently meets and exceeds the dissolution specifications which requires that 80% of the
15 ribavirin be dissolved in water in 30 minutes; about 90% of the ribavirin in the compacted ribavirin compositions of this invention is consistently dissolved in water in 15 minutes and about 100% of the ribavirin from the compositions of this invention is dissolved in 30 minutes. The disintegration time of the ribavirin compositions of this invention was reduced to less than
20 10 minutes compared to the Virazole capsule composition which disintegrated in 20 minutes (see Table 1).

The ribavirin composition of this invention was blended and passed through a roller compactor at a compressing force in the range of about 50 to 75 kiloNewtons ("kN") for a time sufficient to produce an acceptable compact.
25 An "acceptable compact" as used herein means a compact that is in the form of a ribbon which is homogeneous, and almost completely free, i.e., more than 95% free, of lamination and flaking, and substantially free of polymorphic forms of ribavirin. A compressing force in the range of 50 to about 75 kN consistently produced an acceptable compact. Typically suitable screw
30 speeds and (on the Fitzpatrick roller/compactor) roller speeds include (1) a screw speed of 40 revolutions per minute ("RPM") with a roller-speed of 10 RPM; (2) a screw speed of 30 RPM with a roller speed of 7 RPM; and (3) a screw speed of 22 RPM with a roller speed of 5 RPM. No definitive range of screw speeds and roller speeds was able to be deduced from these
35 results. However we have discovered that an acceptable compact is consistently obtainable by maintaining the compressing force in the range of about 50 to about 75 kN. The compacted material is milled, combined with a lubricant and the resulting tap density of the resulting ribavirin composition is

at least 0.6 g/mL and preferably it is significantly higher, e.g., in the range of about 0.75 to about 0.85 g/mL. The compacted ribavirin compositions of this invention surprisingly have substantially uniform physical and chemical characteristics and the ribavirin in the compacted ribavirin composition is substantially free of polymorphic forms of ribavirin, i.e., there are no signs of polymorphic change in the compacted ribavirin as determined by differential scanning calorimetry. This result is particularly surprising in view of the large amount of heat generated during the compaction step which could normally produce polymorphic forms.

10 The rapidly dissolving ribavirin compositions of this invention are stable and have been subjected to three freeze-thaw cycles without any adverse impact upon the physical appearance, tap density, dissolution and disintegration rates.

Typically suitable disintegrants include pharmaceutically acceptable disintegrants which are chemically and physically compatible with ribavirin; preferably those disintegrants are selected from the group consisting of croscarmellose sodium,, sodium starch glycolate, corn starch, pregelatinized starches, sodium carboxymethyl cellulose, potato starch, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, magnesium aluminium silicate, bentonite, alginic acid and alginates.

20 The effective amount of a disintegrant found useful in the ribavirin compositions of this invention is in the range of about 1.0 to about 3.0 weight percent, preferably about 1.5 to about 2.5 weight percent, and most preferably about 2.0 weight percent of the ribavirin compositions of this invention. The preferred disintegrants are croscarmellose sodium and polyvinyl pyrrolidone or mixtures thereof. The most preferred disintegrant is croscarmellose sodium.

Typically suitable lubricants include any pharmaceutically acceptable solid or liquid lubricants which are used to enhance the flow and prevent sticking of the ribavirin composition after compaction and which are chemically and physically compatible with ribavirin.

Typically suitable lubricants include magnesium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG 4000, PEG 5000, PEG 6000, and stearic acid.

35 The effective amount of a lubricant found useful in the ribavirin compositions of this invention is in the range of about 0.75 to about 2.0 weight percent, preferably about 1.0 to about 1.7 weight percent, and most

preferably about 1.3 weight percent of the ribavirin compositions of this invention. The preferred lubricant is magnesium stearate.

Typically suitable fillers include any such pharmaceutically acceptable filler which gives the powder ribavirin composition bulk and which is physically and chemically compatible with ribavirin; preferably those fillers are selected from the group consisting of lactose anhydrous, lactose monohydrate, sucrose, mannitol, microcrystalline cellulose, pregelatinized starches, dibasic calcium phosphate dihydrate, calcium sulfate trihydrate and calcium sulfate dihydrate.

Typically two fillers are used in the ribavirin compositions of this invention. The effective amount of the fillers found useful in the ribavirin compositions of this invention is in the range of about 20 to about 40 weight percent, preferably about 25 to about 35 weight percent, and most preferably about 30 weight percent of the ribavirin compositions of this invention. One of the preferred fillers is lactose monohydrate which is typically present in the range of about 10 to about 15 weight percent, more preferably about 13 to about 14 weight percent of the ribavirin compositions of this invention. The other preferred filler is microcrystalline cellulose which is typically present in the range of about 10 to about 20 weight percent, more preferably about 12 to about 18 weight percent, and most preferably about 16 to about 17 weight percent of the ribavirin compositions of this invention.

The term "tap density" as used herein means the measured mass of a powder attained at a limiting volume measured in a cylinder after being "tapped down", typically by a mechanical device; typically tap density is recorded as mass in grams divided by volume in milliliters ("mL"). The tap density is measured in accordance with the procedure described in USP 23, NF 18, Supplement 6, (1997), procedure <616> at page 3768. The tap density of the orally administrable ribavirin composition of this invention is at least 0.6 g/mL which is advantageous when a capsule containing 200 mg of ribavirin in the 300 mg preferred composition of this invention is used.

Typically the tap densities of the orally administrable ribavirin is in the range of about 0.75 g/mL to about 0.85 g/mL.

While the rapidly dissolving ribavirin compositions of this invention are described for 200 mg ribavirin strengths as capsules or tablets, other strengths e.g., 300 or 400 mg of ribavirin, may be used without deviating from this invention.

Ribavirin (1600-1200 mg in single or divided daily doses such as 600 mg QD or 600 mg BID or 400mg TID) is being used in clinical trials in

combination with subcutaneous injections of interferon alfa-2b (3 million international units, three times a week (TIW)) to treat chronic hepatitis C patients. Thus, the term antivirally effective amount of ribavirin as used herein means dosages of ribavirin, e.g., 200 mg, 300 mg or 400 mg as tablets
5 or capsules, which would provide the 600-1200 mg/day, preferably 800-1200 mg/day or 1000-1200 mg/day of ribavirin used to treat chronic hepatitis C patients in combination with the interferon alfa-2b. The ribavirin compositions of this invention may be filled into capsules or compressed into tablets.

10

Manufacturing Procedure

General Manufacturing Procedure

15

(1) Charge the ribavirin, one or more fillers and disintegrant into a suitable double cone blender.

(2) Blend the charge from step (1) for a time sufficient to form uniform blend.

20

(3) Optionally pass the blend of step (2)-if the such blend should contain lumps- through a suitable comminutor mill set at medium speed to provide a lump-free blend.

25

(4) Pass the milled uniform blend from step 2 or 3 through a suitable roller/compactor equipped with an oscillator for screening and operated at a compressing force of about 50 to about 70 kN for a time sufficient to produce an acceptable compact;

(5) Combine the compacted screened blend from step (4) and charge said blend to the blender used in step (1).

30

(6) Charge the lubricant to the blend from step (5) and blend the mixture for a time sufficient to produce a uniform mixture;

(7) Fill the uniform mixture from step (6) into capsules.

35

A large scale batch of the capsule formulation was prepared using the formulations of Example 1 or 2.

Procedure:

- 5 1. Charge the ribavirin, microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium into a suitable double cone blender of appropriate volume.
- 10 2. Blend the charge in step (1) for 10 to 15 minutes, preferably about 15 minutes. Discharge the so-formed mixture into plastic lined containers.^a
- 15 3. Optionally pass the blended mixture in step (2) through a suitable comminutor mill set at medium speed, impact hammers forward fitted with a No. 6 mesh screen. (This step is optional and may be eliminated if the blended mixture from step (2) is lump-free.)
- 20 4. Pass the milled blend in step 2 or 3 through a suitable roller/compactor such as a Bepex or Fitzpatrick roller compactor machine equipped with an oscillator for screening. Operate the roller compactor at a compressing force of about 50 to about 75 kN for a time sufficient to produce an acceptable compact. (An acceptable compact is normally produced with a single pass of the milled blend from step (3) through the compactor. The compacted material is thereafter directly fed into the oscillating mill equipped with a 16 mesh screen.)
- 25 5. Combine the compacted, screened blend in step 4 and charge the blend to the blender used in Step 1. Blend for 10 minutes. Remove samples of the blend for tap density and sieve analysis testing.
- 30 6. Charge the magnesium stearate to the blend in step 5 and blend for about 3 minutes or a time sufficient to produce a uniform mixture.
- 35 7. Fill the uniform mixture in Step 6 into No. 1 white opaque, two-piece hard gelatin capsules using an appropriate high speed capsule filling equipment, e.g., a Zanasi AZ40 or H&K 1500.

8. Polish and dedust the filled capsules using a rotating brush capsule polishing machine, e.g., Key Turbo-Kleen CP-300 equipped with an empty capsule eliminator.

5

Footnote

a. Analyze the blended mixture from step (2) for blend uniformity. Based on this analysis, it was then determined that a blending time of 10 to 15 minutes was sufficient to produce an acceptable blend uniformity.

10

Ribavirin is mutagenic and teratogenic and appropriate precautions must be taken to ensure the safety of the manufacturing personnel.

The following examples illustrate, but do not limit, the present invention:

15

Example 1

The above-described manufacturing procedure may be used to blend, compact, and mill the following compositions:

20

<u>Ingredient</u>	<u>mg</u>
Ribavirin USP	150.0 to 250.0
Lactose Monohydrate NF	30.0 to 50.0
Microcrystalline Cellulose NF	37.5 to 62.5
25 Croscarmellose Sodium NF	4.5 to 7.5
Magnesium Stearate NF	2.25 to 5.0

The above compositions have tap densities of at least 0.6 g/mL.

30

Example 2

The procedure of Example 1 was followed to prepare the following
5 composition:

	<u>Ingredient</u>	<u>mg</u>
	Ribavirin USP	200.0
	Lactose Monohydrate NF 1	40.0
10	Microcrystalline Cellulose NF	50.0
	Croscarmellose Sodium NF	6.0
	Magnesium Stearate NF	<u>4.0</u>
	Total	300

The tap density was 0.77 g/mL.

15 (1) Preferably the lactose monohydrate NF is spray dried.

The composition was filled into capsules and the following dissolution
results were recorded:

	Weight %, Ribavirin	Wgt% Ribavirin Dissolved
20	<u>Dissolved(average) (Range)</u>	
	<u>Time (minutes)</u>	
	15	99 (93 - 103)
25	30	101 (98 - 103)
	45	101 (98 - 104)
	60	102 (99 - 104)

12 capsules of the formulation of Example 2 were tested using a USP
30 basket at 100 RPM in 900 mL of distilled water operated in accordance with
the procedure described in USP 23, NF-18, procedure <711>.

The formulation of Example 2 exhibited no signs of polymorphic
changes in the ribavirin as determined by differential scanning calorimetry.
USP 23, NF-18 Supplement 6, procedure <891>, 1997.

35 The disintegration time for the formulation of Example 2 was
measured as described in Table 1; the capsules disintegrated in 7 - 9
minutes.

The effect of freeze-thaw cycling was determined for the formulation of
Example 2 in capsules. The capsules were subjected to three freeze-thaw

cycles. The first two freeze and thaw cycles lasted 24 hours. The last freeze-thaw cycle was 72 hours followed by 24 hours at ambient - i.e. room temperatures..

Physical observation, disintegration, and dissolution studies were performed. No significant change in physical appearance the disintegration time or dissolution rates were observed compared to the initial test results.

10	Weight %Ribavirin Dissolved		Weight %Ribavirin Dissolved
	<u>Time (minutes)</u>	<u>Avg. for a capsule</u>	<u>Range</u>
	15	93	(84 - 100)
15	30	96	(89 - 100)
	45	96	(86 - 101)
	60	96	(86-101)

Essentially no changes were observed in the tap density, dissolution or disintegration rates of the ribavirin composition of Example 2.

Example 3

The following composition represents the composition of a typical Virazole 200 mg capsule (uncompacted):

30	<u>Ingredient</u>	<u>mg</u>
	Ribavirin USP	200.0
	Lactose Monohydrate NF Spray Dried	46.0
	Microcrystalline Cellulose NF	50.0
	Magnesium Stearate NF	<u>4.0</u>
	Capsule Fill Weight	300.0
	Capsule Size	No. 1
	Capsule Type	White Opaque

Table 1

5

Comparative dissolution and disintegration results for the rapidly dissolving ribavirin composition of Examples 2 and 3:

A. Dissolution			
		<u>Weight % Ribavirin Dissolved</u>	
	<u>Time</u>	<u>Compacted Ribavirin¹</u>	<u>Virazole Composition²</u>
15	15	91	84
	30	98	96
	45	99	
	60	99	

B. Disintegration ³		
	<u>Product</u>	<u>Disintegration Time (minutes)</u>
25	Compacted ribavirin composition of Example 2 of this invention	6 - 8
	Virazole composition of Example 3	~ 20

1. 12 capsules of Example 2 were tested man USP basket at 100 RPM in 900 mL of distilled water operated in accordance with the procedure described in USP 23, NF 18, procedure <711>, 1995.

35

2. The uncompacted Virazole composition of Example 3 was used.

40

3. 6 capsules were tested in an USP apparatus operated in accordance with the procedure described in USP 23 NF 18 procedure <701>, 1995.

45

Other modification may be made in this invention without deviating from the scope of the present inventor. For example, the formulations of Examples 1 or 2 may be modified by substituting a portion of the croscarmellose sodium with polyvinylpyrrolidone and the so-formed composition may be compressed into tablets.

What is claimed is:

1. An orally administrable solid dosage form comprising a rapidly
5 dissolving ribavirin compacted composition comprising ribavirin and a pharmaceutically acceptable disintegrant wherein said composition has a tap density of at least about 0.6 g/mL and wherein more than about 80% by weight of the ribavirin dissolves in water in about 30 minutes.
- 10 2. A rapidly dissolving compacted ribavirin composition comprising:
 - (a) an antivirally effective amount of ribavirin;
 - (b) an effective amount of at least one filler selected from the group
15 consisting of lactose anhydrous lactose monohydrate, sucrose, mannitol, microcrystalline cellulose, pregelatinized starches, dibasic calcium phosphate dihydrate, calcium sulfate dihydrate and calcium sulfate trihydrate;
 - (c) an effective amount of a pharmaceutically acceptable
20 disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, corn starch, pregelatinized starch, sodium carboxymethyl cellulose, potato starch, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, magnesium aluminium silicate, bentonite, alginic acid and alginates;
25 and;
 - (d) an effective amount of a lubricant selected from the group
30 consisting of magnesium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG 4000, PEG 5000, PEG 6000, and stearic acid;and, wherein the tap density of the compacted composition is at least about 0.6 g/mL.
- 35 3. The orally administrable solid dosage form of claim 1 wherein the composition comprises about 200 to 400 mg of ribavirin.

4. A rapidly dissolving compacted ribavirin composition comprising:

	<u>Ingredient</u>	<u>mg</u>
5	Ribavirin USP	150.0 to 250.0
	Lactose Monohydrate NF	30.0 to 50.0
	Microcrystalline Cellulose NF	37.5 to 62.5
	Croscarmellose Sodium NF	4.5 to 7.5
	Magnesium Stearate NF	2.25 to 5.0

10

and wherein the tap density of the compacted composition is at least about 0.6 g/mL.

5. The orally administrable solid dosage form of any preceeding claim
15 wherein the disintegrant is croscarmellose sodium or polyvinylpyrrolidone or mixtures thereof.

6. The rapidly dissolving compacted ribavirin composition of any
preceeding claim wherein the ribavirin is substantially free of polymorphic
20 forms of ribavirin.

7. The rapidly dissolving compacted ribavirin composition of claim 4
wherein more than about 80% by weight of the ribavirin dissolves in water in
about 30 minutes.

25

8. The rapidly dissolving compacted ribavirin composition of claim 4
wherein the disintegration time of the composition is less than about 10
minutes.

9. The rapidly dissolving compacted ribavirin composition of claim 4
30 wherein the tap density of the composition is in the range of about 0.75 g/mL to about 0.85 g/mL.

10. The rapidly dissolving compacted ribavirin composition of any
35 preceeding claim in the form of a tablet or capsule.

11. A method of producing a rapidly dissolving compacted ribavirin
composition which comprises the steps of:

5 (a) admixing an antivirally effective amount of ribavirin, an effective amount of a pharmaceutically acceptable disintegrant, and an effective amount of at least one filler for a time sufficient to form a homogeneous mixture;

10 b) compacting the homogeneous mixture of Step (a) at a compressing force in the range of about 50 to about 75 kN for a time sufficient to produce an acceptable compact wherein the ribavirin is substantially free of polymorphic forms of ribavirin; and

15 c) admixing the acceptable compact of Step (b) with an effective amount of a lubricant for a time sufficient to produce a uniform, rapidly dissolving compacted ribavirin composition.

20 12. The method of claim 11 wherein the rapidly dissolving compacted ribavirin has a tap density of at least about 0.60 g/mL and preferably the rapidly dissolving compacted ribavirin has a tap density oin the range of about 0.75 g/mL to about .0.85 g/mL.

25 13. The method of claim 11 wherein more than about 80% of the rapidly dissolving compacted ribavirin composition dissolves in water in about 30 minutes and preferably more than about 90% of the rapidly dissolving compacted ribavirin composition dissolves in water in about 15 minutes.

30 14. The method of claim 11 wherein at least one filler is selected from the group consisting of lactose anhydrous, lactose monohydrate, sucrose, mannitol, microcrystalline cellulose, pregelatinized starches, dibasic calcium phosphate dihydrate, calcium sulfate dihydrate and calcium sulfate trihydrate.

35 15. The method of claim 11 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate, corn starch, pregelatinized starch, sodium carboxymethyl cellulose, potato starch, microcrystalline cellulose, polyvinylpyrrolidone, cross-linked

polyvinylpyrrolidone, magnesium aluminium silicate, bentonite, alginic acid and alginates

16. The method of claim 1 wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG 4000, PEG 5000, PEG 6000, and stearic acid.

17. A rapidly dissolving compacted ribavirin composition comprising:

10	<u>Ingredient</u>	<u>mg</u>
	Ribavirin USP	200.0
	Lactose Monohydrate NF	40.0
	Microcrystalline Cellulose NF	50.0
	Croscarmellose Sodium NF	6.0
15	Magnesium Stearate NF	4.0

wherein the tap density of the compacted composition is at least about 0.6 g/mL;

- and wherein the ribavirin is substantially free of polymorphic forms of ribavirin; and

wherein more than about 80% by weight of the compacted composition dissolves in water in about 30 minutes.

18. The rapidly dissolving compacted ribavirin composition of claim 17 wherein said composition is in the form of a capsule.

19. The rapidly dissolving compacted ribavirin composition of claim 17 wherein more than about 90% by weight of the compacted composition dissolves in water in about 15 minutes.

20. The rapidly dissolving compacted ribavirin composition of claim 17 wherein the tap density of the compacted composition is in the range of about 0.75 g/mL to about 0.85 g/mL

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/26222

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/70 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 211 771 A (ROBINS RONALD K ET AL) 8 July 1980 see column 1, line 61 - column 2, line 6 see column 6, line 11-38 see column 8, line 1-14 see claims 1,9	1-4,10, 17,18
A	CA 2 135 669 A (ICN PHARMACEUTICALS) 11 May 1996 see page 1, line 1-3 see page 7, line 28 - page 9, line 2 --- -/--	1-4,10, 17,18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

06/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

La Gaetana, R

INTERNATIONAL SEARCH REPORT

I. national Application No

PCT/US 98/26222

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 4 609 675 A (FRANZ ROBERT M) 2 September 1986 see column 1, line 10-30 see column 3, line 17-30 see column 5, line 24-46 see column 7, line 27-44 see column 8, line 39 - column 9, line 5 see example 5 see claim 3</p> <p style="text-align: center;">---</p>	<p>11-13, 15,16</p>
A	<p>BOTZOLAKIS JE, AUGSBURGER LL: "The role of disintegrants in hard-gelatin capsules" JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 36, no. 2, 1984, pages 77-84, XP002100982 See pages 77-78, paragraph "Materials and formulations" See page 78, paragraph "Preparation of capsules" see page 79; table 1</p> <p style="text-align: center;">-----</p>	<p>11,13-16</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. ...national Application No

PCT/US 98/26222

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4211771 A	08-07-1980	US 3927216 A	16-12-1975
		AR 199463 A	09-09-1974
		AT 336199 B	25-04-1977
		AT 465772 A	15-08-1976
		AU 461900 B	12-06-1975
		AU 4215772 A	20-12-1973
		BE 784195 A	30-11-1972
		BG 22827 A	20-04-1977
		CA 997756 A	28-09-1976
		CH 614452 A	30-11-1979
		CS 183661 B	31-07-1978
		DD 99791 A	20-08-1973
		DE 2220246 A	14-12-1972
		DK 143069 B	23-03-1981
		DK 509776 A, B,	12-11-1976
		DK 509876 A	12-11-1976
		EG 11406 A	30-06-1981
		FR 2140126 A	12-01-1973
		GB 1353565 A	22-05-1974
		HK 23876 A	30-04-1976
		IE 36478 B	10-11-1976
		IN 142290 A	18-06-1977
		JP 53095974 A	22-08-1978
		JP 55019238 B	24-05-1980
		JP 53087356 A	01-08-1978
		JP 55019239 B	24-05-1980
		JP 53124271 A	30-10-1978
		JP 53108973 A	22-09-1978
		LU 65446 A	05-10-1972
		MC 921 A	25-01-1973
		NL 7207156 A	05-12-1972
		SE 405604 B	18-12-1978
		SE 7801925 A	20-02-1978
		SE 7801926 A	20-02-1978
		US 3897415 A	29-07-1975
		US 3798209 A	19-03-1974
		US 3984396 A	05-10-1976
		US 3991078 A	09-11-1976
		US RE29835 E	14-11-1978
		ZA 7203239 A	28-02-1973
		AR 205339 A	30-04-1976
		AU 6670874 A	18-09-1975
		BE 812191 A	01-07-1974
		BE 903675 A	20-05-1986
		CH 602785 A	15-08-1978
		DE 2411823 A	26-09-1974
		FR 2221138 A	11-10-1974
		FR 2289520 A	28-05-1976
		GB 1427304 A	10-03-1976
		IE 38987 B	05-07-1978
CA 2135669 A	11-05-1996	NONE	
US 4609675 A	02-09-1986	EP 0172014 A	19-02-1986
		JP 61057522 A	24-03-1986